Drug guidance
Cabotegravir with rilpivirine for treating Human Immunodeficiency Virus type 1 (HIV-1) infection
Condition
Infections
13 September 2024
Published on 13 Sep 2024
Last Updated on 13 Sep 2024
Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has not recommended cabotegravir with rilpivirine for inclusion on the MOH List of Subsidised Drugs for treating Human Immunodeficiency Virus type 1 (HIV-1) infection. The decision was based on the unfavourable cost-effectiveness of cabotegravir with rilpivirine at the price proposed by the company compared with subsidised oral antiretroviral therapies.